AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00658372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
Study NCT00658372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
Study NCT00658372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, oral, placebo, BID, 8 weeks with 2 week taper
Study NCT01333202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh lime
Description: fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
Study NCT01333202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh lime
Description: fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
Study NCT01426087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: giving stilamin 250ug/h after endoscopic therapy for 5 days
Study NCT01426087 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic therapy
Description: gastroscope plus EIS/EVL/HI
Study NCT02262559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277 tablet
Study NCT02262559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 277 capsule
Study NCT01985464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Study NCT02546024 — intervention group
Intervention type: DRUG
Intervention: Standard care
Description: Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
Study NCT02320162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential learning oral health education
Study NCT02320162 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experiential learning oral health education
Study NCT03052855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) and biological samples
Description: Participants will have to do a MRI and biological samples.
Study NCT03496987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Bottle Drainage
Description: Patients undergo drainage via vacuum bottles
Study NCT01589640 — intervention group
Intervention type: OTHER
Intervention: Blink Tears lubricating Eye Drops
Description: 2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
Study NCT01589640 — intervention group
Intervention type: OTHER
Intervention: Blink Gel Tears Lubricating Eye Drops
Description: 2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
Study NCT01589640 — intervention group
Intervention type: OTHER
Intervention: Systane Balance Lubricant Eye Drop
Description: 2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
Study NCT00723632 — intervention group
Intervention type: BIOLOGICAL
Intervention: peginterferon alfa-2b
Description: Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
Study NCT00723632 — intervention group
Intervention type: DRUG
Intervention: ribavirin
Description: Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants >65 to \<85 kg, and 1200 mg/day for participants >=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
Study NCT02756585 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ct perfusion
Description: computed tomography perfusion of the head
Study NCT01838733 — intervention group
Intervention type: OTHER
Intervention: Observational study
Study NCT00761137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg tropicamide
Description: 0.3 mg tropicamide in intra-oral thin film
Study NCT03638622 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
Study NCT01435902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
Study NCT00761137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg tropicamide
Description: 1 mg tropicamide in intra-oral thin film
Study NCT00761137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg tropicamide
Description: 3 mg tropicamide in intra-oral thin film
Study NCT01435902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Inhalation Powder
Description: Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
Study NCT03867279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flossing
Description: The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
Study NCT03867279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reeducation exercises
Description: The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
Study NCT04361825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects > 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
Study NCT03189420 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor resection
Description: The tumors will be resected in routine therapeutic surgeries
Study NCT01570166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR
Description: HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
Study NCT01570166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
Study NCT01515878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemocontrol
Description: Blood Volume Tracking system using biofeedback
Study NCT04344548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK transfer
Description: Three doses of allogeneic NK cell transfer
Study NCT04298515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nesfatin-1
Description: Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
Study NCT00865670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Monohydrate 600 mg Tablets
Study NCT00865670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax (azithromycin dihydrate) 600 mg Tablets
Study NCT01332084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HA wheat cereals
Description: HA wheat cereals used in SOTI test and as part of desensitization plan
Study NCT03882190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
Study NCT02158975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Study NCT01997853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
Study NCT01997853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
Study NCT02840721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: PF-06480605 500 mg IV Q2W x 7 Doses
Study NCT00934479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
Study NCT02096679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
Study NCT02866708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure device
Description: This intervention study will be designed as a randomized cross-over study.
Study NCT01758523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study NCT01758523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Study NCT03148314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: (800µgm.x 2 doses 3 hours).
Study NCT03148314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buccal/sublingual misoprostol
Description: 200 µgm.x4 hrs.x 6 doses
Study NCT02583126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Music
Description: Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
Study NCT03646825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Natural Antioxidant supplement
Description: 1 capsule orally three times a day for 12 weeks
Study NCT04330053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: * Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour.
Study NCT04330053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: * Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home.
Study NCT03504254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI examination
Description: Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
Study NCT01810861 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in this study
Description: This is a non-interventional study.
Study NCT00193258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV infusion every 2 weeks
Study NCT00193258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg po daily
Study NCT00193258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400-600mg daily
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Cupping
Description: Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Other intervention(s)
Description: Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
Study NCT04798521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-HCV
Description: Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
Study NCT04798521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Linkage to Care
Description: Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
Study NCT00761137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg tropicamide
Description: 0 mg tropicamide (placebo) in intra-oral thin film
Study NCT02411227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Driving
Description: Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
Study NCT01751997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transplants from 8/8-matched Unrelated donors
Description: * Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age > 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11
Study NCT01751997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplants from family-mismatched/haploidentical donors
Description: * Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11
Study NCT03210727 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ready to CARE program
Description: The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion.
Study NCT02191202 — intervention group
Intervention type: DRUG
Intervention: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Study NCT01087528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ (Capsule Endoscopy) Colon 2 capsule
Description: Medical Device
Study NCT03955419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NO-NPO (Daesang WelLife Co., Ltd., Korea)
Description: 800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
Study NCT01343654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging plus EMA
Description: Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
Study NCT01343654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
Study NCT01126840 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone Interview
Description: The phone interview should take 30-45 minutes to complete.
Study NCT01126840 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.